Assessing Cigna Group (CI) Valuation As Specialty Pharmacy Growth Meets Choppy Recent Returns

Simply Wall St.01-09

Advertisement Cigna Group (CI) remains in focus for investors after recent trading left the stock around $279.12, with returns mixed across different periods and financial results that include revenue...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602397535?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/172899-main-header/1756254126085","is_english":true,"pubTime":"2026-01-09 02:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602397535","market":"us","top_or_hot":-1,"title":"Assessing Cigna Group (CI) Valuation As Specialty Pharmacy Growth Meets Choppy Recent Returns","media":"Simply Wall St.","content":"<div>\n<p>Advertisement Cigna Group (CI) remains in focus for investors after recent trading left the stock around $279.12, with returns mixed across different periods and financial results that include revenue...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-ci/cigna-group/news/assessing-cigna-group-ci-valuation-as-specialty-pharmacy-gro\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Cigna Group (CI) Valuation As Specialty Pharmacy Growth Meets Choppy Recent Returns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Cigna Group (CI) Valuation As Specialty Pharmacy Growth Meets Choppy Recent Returns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-09 02:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-ci/cigna-group/news/assessing-cigna-group-ci-valuation-as-specialty-pharmacy-gro><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Advertisement Cigna Group (CI) remains in focus for investors after recent trading left the stock around $279.12, with returns mixed across different periods and financial results that include revenue...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-ci/cigna-group/news/assessing-cigna-group-ci-valuation-as-specialty-pharmacy-gro\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1059921491.USD","symbol_name":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-ci/cigna-group/news/assessing-cigna-group-ci-valuation-as-specialty-pharmacy-gro","article_id":"2602397535","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/172899-main-header/1756254126085"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-ci/cigna-group/news/assessing-cigna-group-ci-valuation-as-specialty-pharmacy-gro","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602397535","pubTimestamp":1767897647,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Cigna Group (CI) remains in focus for investors after recent trading left the stock around $279.12, with returns mixed across different periods and financial results that include revenue of about $268.1 billion and net income of roughly $6.1 billion.\nSee our latest analysis for Cigna Group.\nRecent trading has been choppy, with a 1 day share price return of about a 2% decline and a 90 day share price return of an 8.8% decline. The 5 year total shareholder return of 36.3% points to steadier...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4196":"保健护理服务","LU1261432733.SGD":"Fidelity World A-ACC-SGD","BK4588":"碎股","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","CI":"信诺保险","BK4585":"ETF&股票定投概念","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD"},"translate_title":"随着专业药房增长遇到近期回报波动，评估信诺集团(CI)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CI":1.5},"content_text":"Advertisement Cigna Group (CI) remains in focus for investors after recent trading left the stock around $279.12, with returns mixed across different periods and financial results that include revenue of about $268.1 billion and net income of roughly $6.1 billion. See our latest analysis for Cigna Group. Recent trading has been choppy, with a 1 day share price return of about a 2% decline and a 90 day share price return of an 8.8% decline. The 5 year total shareholder return of 36.3% points to steadier long term progress, suggesting shorter term momentum has been fading even as longer term holders have still seen gains. If Cigna’s moves have you thinking about where else to put your money to work, this could be a good moment to scan other healthcare stocks that might fit your portfolio. With Cigna trading around $279.12, carrying a value score of 5, an intrinsic discount of about 66%, and a price target near $326, you have to ask: is this a genuine mispricing, or is the market already baking in future growth? Most Popular Narrative: 14.3% Undervalued Compared with Cigna Group’s last close at about $279.12, the most followed narrative points to a fair value near $325.57, implying meaningful upside in that framework. Cigna is capitalizing on the growing demand for specialty pharmacy and care services, particularly as chronic diseases and complex treatments become more prevalent. The double-digit revenue growth in CuraScript and Accredo positions the company to capture an expanding portion of the high-growth $400B+ specialty space, supporting long-term revenue and earnings growth. Read the complete narrative. Want to see what is behind that specialty pharmacy story and the fair value estimate? The narrative leans heavily on future revenue, margins and the profit multiple applied to those earnings. Curious which assumptions really carry the model and how sensitive that $325.57 figure is to them? Read on and decide whether those expectations line up with your own view. Result: Fair Value of $325.57 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this story can change quickly if tighter PBM regulation hits Evernorth margins, or if Cigna’s reduced focus on government programs limits future revenue opportunities. Find out about the key risks to this Cigna Group narrative.  Build Your Own Cigna Group Narrative If the current story does not quite match your view, you can dig into the numbers yourself, stress test the assumptions, and Do it your way in a few minutes. A great starting point for your Cigna Group research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision. Looking for more investment ideas? If you are weighing what to do next after looking at Cigna, do not stop here. Broaden your watchlist and give yourself more options to compare.  Target potential mispricings by checking stocks that screen as undervalued on cash flows, starting with these 879 undervalued stocks based on cash flows that might deserve a closer look. Capture growth themes early by scanning these 27 AI penny stocks tied to artificial intelligence, where business models are closely linked to data, software, and automation. Add income ideas to your shortlist by reviewing these 12 dividend stocks with yields > 3% that focus on cash returns to shareholders through higher yielding payouts.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602397535","isCrawlerRequest":true}